Molecular modeling of adenosine receptors: New results and trends

Medicinal Research Reviews

Volumn 28, Issue 2, 2008, Pages 247-277

  Martinelli, Adriano ^a   Tuccinardi, Tiziano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Adenosine receptors; Docking; Homology modeling; Site directed mutagenesis

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; RHODOPSIN;

ALLOSTERISM; BIOLOGY; EXPERIMENTATION; HUMAN; MOLECULAR MODEL; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURAL HOMOLOGY; VALIDATION STUDY; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANIMALS; CATTLE; COMPUTER SIMULATION; DOGS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RATS; RECEPTORS, PURINERGIC P1; RHODOPSIN; SEQUENCE ALIGNMENT;

EID: 39549089521     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20106     Document Type: Review

References (154)

1. Tabrizchi R, Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther 2001;91:133-147.
2. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990;70:761-845.
3. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000;362:299-309.
4. Volmer JB, Thompson LF, Blackburn MR. Ecto-5′-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol 2006;176:4449-4458.
5. Arch JR, Newsholme EA. Activities and some properties of 5′-nucleotidase, adenosine kinase and adenosine deaminase in tissues from vertebrates and invertebrates in relation to the control of the concentration and the physiological role of adenosine. Biochem J 1978;174:965-977.
6. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-552.
7. Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hr after ischemic preconditioning. Circulation 1994;90:2993-3000.
8. Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the delayed phase of myocardial protection: Repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 1998;31:1142-1149.
9. 1-Adenosine receptor antagonists. Expert Opin Ther Pat 1997;7:419-440.
10. Hess S. Recent advances in adenosine receptor antagonist research Expert Opin Ther Pat 2001;11:1533-1561.
11. Stone TW, Collis MG, Williams M, Miller LP, Karasawa A, Hillaire-Buys D. In Pharmacological sciences: Perspectives for research and therapy in the late 1990s. Int Cong Pharmacol 1994; 303-309.
12. Miller DD. Impact of selective adenosine A2A receptor agonists on cardiac imaging feeling the lightning, waiting on the thunder. J Am Coll Cardiol 2005;46:2076-2078.
13. Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-344.
14. Baraldi PG, Cacciari B, Spalluto G, Borioni A, Viziano M, Dionisotti S, Ongini E. Current developments of A2A adenosine receptor antagonists. Curr Med Chem 1995;2:707-722.
15. Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol Ther 2005;105:267-310.
16. Pinna A, Wardas J, Simola N, Morelli M. New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists. Life Sci 2005;77:3259-3267.
17. Kase H, Seno N, Mori A, Zhao D. Adenosine A2A receptor antagonists for treating restless legs syndrome or related disorders. PCT Int. Appl. WO 2004019949; 2004.
18. Feoktistov I, Biaggioni I. Adenosine A2B receptors evoke interleukine-S secretion in human mast cells: An enprofyllinesensitive mechanism with implication for asthma. J Clin Invest 1995;96:1979-1986.
19. Boyle DL, Sajjadi FG, Firestein GS. Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 1996;39:923-930.
20. Dubey RK, Gillaspie DG, Osaka K, Suzuki F, Jackson EK. Adenosine inhibits growth of rat aortic smooth muscle cells: Possible role of A2B receptors. Hypertension 1996;27:786-793.
21. Murthy KS, McHenry L, Grider JR, Makhlouf GM. Adenosine A1 and A2B receptors coupled to distinct interactive signaling pathways in intestinal muscle cells. J Pharmacol Exp Ther 1995;274:243-246.
22. Rubino A, Ralevic V, Burnstock G. Contribution of P1 (A2Bsubtype) and P2-purinoceptors to the control of vascular tone in the rat isolate mesenteric arterial bed. Br J Pharmacol 1995;115:648-652.
23. Liang BT, Jacobson KA. A physiological role of the adenosine A3 receptor: Sustained cardioprotection. Proc Natl Acad Sci USA 1998;95:6995-6999.
24. Fishman P, Bar-Yehuda S, Madi L, Cohn I. A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 2002;13:437-443.
25. Jacobson KA. Adenosine A3 receptors: Novel ligands and paradoxical effects. Trends Pharmacol Sci 1998;19:184-191.
26. Ramkumar V, Stiles GL, Beaven MA, Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993;268:16887-16890.
27. Muller CE. Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem 2003;3:445-462.
28. Caffrey M. Membrane protein crystallization. J Struct Biol 2003;142:108-132.
29. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000;289:739-745.
30. Holgate ST. The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol 2005;145:1009-1015.
31. Kakazu C, Lippmann M, White RA. Additional use for adenosine in anaesthesia and surgery. Br J Anaesth 2005;95:836-837.
32. 3 adenosine receptor ligands. Expert Opin Ther Pat 2005;15:1507-1519.
33. 2A agonists in development for the treatment of inflammation. Expert Opin Invest Drugs 2005;14:797-806.
34. Mora S, Spalluto G, Jacobson KA. Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. Trends Pharmacol Sci 2005;26:44-51.
35. Cacciari B, Pastorin G, Bolcato C, Spalluto G, Bacillen M, Moro S. A2B adenosine receptor antagonists: Recent developments. Mini Rev Med Chem 2005;5:1053-1060.
36. Polosa R, Volgate ST. Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation. Curr Drug Targets 2006;7:699-706.
37. Russo C, Arcidiacono G, Polosa R. Adenosine receptors: Promising targets for the development of novel therapeutics and diagnostics for asthma. Fund Clin Pharmacol 2006;20:9-19.
38. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nature Rev Drug Disc 2006;5:247-264.
39. Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev 2006;26:131-159.
40. Dal Ben D, Lambertucci C, Vittori S, Volpini R, Cristalli G. GPCRs as therapeutic targets: A view on adenosine receptors structure and functions, and molecular modeling support. J Iran Chem Soc 2005;2:176-188.
41. Moro S, Deflorian F, Bacilieri M, Spalluto G. Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity. Curr Pharm Des 2006;12:2175-2185.
42. Westbrook J, Feng Z, Chen L, Yang H, Berman HM. The Protein Data Bank and structural genomics. Nucleic Acids Res 2000;28:235-242.
43. Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001;40:7761-7772.
44. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 2004;343:1409-1438.
45. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci USA 2002;99:5982-5987.
46. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure. J Mol Biol 2004;342:571-583.
47. Mirzadegan T, Benko G, Filipek S, Palczewski K. Sequence analyses of G-protein-coupled receptors: Similarities to rhodopsin. Biochemistry 2003;42:2759-2767.
48. Martinelli A, Tuccinardi T. An overview of recent developments in GPCR modelling: Methods and validation. Expert Opin Drug Discov 2006;1:459-476.
49. http://www.gpcr.org/7tm/
50. Ballesteros JA, Weinstein HW. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci 1995;25:366-428.
51. Kim SK, Gao ZG, Van Rompaey P, Gross AS, Chen A, Van Calenbergh S, Jacobson KA. Modeling the adenosine receptors: Comparison of the binding domains of A2A agonists and antagonists. J Med Chem 2003;46:4847-4859.
52. Olah ME, Jacobson KA, Stiles GL. Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. J Biol Chem 1994;269:24692-24698.
53. Rivkees SA, Barbhaiya H, IJzerman AP. Identification of the adenine binding site of the human A1 adenosine receptor. J Biol Chem 1999;274:3617-3621.
54. Barbhaiya H, McClain R, Ijzerman A, Rivkees SA. Site-directed mutagenesis of the human A1 adenosine receptor: Influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Mol Pharmacol 1996;50:1635-1642.
55. Scholl DJ, Wells JN. Serine and alanine mutagenesis of the nine native cysteine residues of the human A1 adenosine receptor. Biochem Pharmacol 2000;60:1647-1654.
56. Xie KQ, Cao Y, Zhu XZ. Role of the second transmembrane domain of rat adenosine A1 receptor in ligand-receptor interaction. Biochem Pharmacol 2006;71:865-871.
57. Olah ME, Ren H, Ostrowski J, Jacobson KA, Stiles GL. Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis. J Biol Chem 1992;267:10764-10770.
58. Tucker AL, Robeva AS, Taylor HE, Holeton D, Bockner M, Lynch KR, Linden J. A1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition. J Biol Chem 1994;269:27900-27906.
59. Townsend-Nicholson A, Schofield PR. A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. J Biol Chem 1994;269:2373-2376.
60. Dawson ES, Wells JN. Determination of amino acid residues that are accessible from the ligand binding crevice in the seventh transmembrane-spanning region of the human A1 adenosine receptor. Mol Pharmacol 2001;59:1187-1195.
61. Gao ZG, Jiang Q, Jacobson KA, Ijzerman AP. Site-directed mutagenesis studies of human A2A adenosine receptors: Involvement of Glu13 and His278 in ligand binding and sodium modulation. Biochem Pharmacol 2000;60:661-668.
62. IJzerman AP Von Frijtag Drabbe Kunzel JK, Kim J, Jiang Q, Jacobson KA. Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition. Eur J Pharmacol 1996;310:269-272.
63. Jiang Q, Lee BX, Glashofer M, van Rhee AM, Jacobson KA. Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem 1997;40:2588-2595.
64. Jiang Q, Van Rhee AM, Kim J, Yehle S, Wess J, Jacobson KA. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharmacol 1996;50:512-521.
65. Kim J, Jiang Q, Glashofer M, Yehle S, Wess J, Jacobson KA. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol 1996;49:683-691.
66. Kim J, Wess J, van Rhee AM, Schoneberg T, Jacobson KA. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem 1995;270:13987-13997.
67. Beukers MW, den Dulk H, van Tilburg EW, Brouwer J, Ijzerman AP. Why are A2B receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A2B receptor for 2-(1-hexynyl)adenosine. Mol Pharmacol 2000;58:1349-1356.
68. Beukers MW, van Oppenraaij J, van der Hoorn PP, Blad CC, den Dulk H, Brouwer J, IJzerman AP. Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. Mol Pharmacol 2004;65:702-710.
69. Linden J, Taylor HE, Robeva AS, Tucker AL, Stehle JH, Rivkees SA, Fink JS, Reppert SM. Molecular-cloning and functional expression of sheep A3 adenosine receptor with widespread tissue distribution. Mol Pharmacol 1993;44:524-532.
70. Linden J. Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 1994;15:298-306.
71. Gao ZG, Kim SK, Gross AS, Chen A, Blaustein JB, Jacobson KA. Identification of essential residues involved in the allosteric modulation of the human A3 adenosine receptor. Mol Pharmacol 2003;63:1021-1031.
72. Chen A, Gao ZG, Barak D, Liang BT, Jacobson KA. Constitutive activation of A3 adenosine receptors by site-directed mutagenesis. Biochem Biophys Res Commun 2001;284:596-601.
73. Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, Kim SG, Johnson CR, Jacobson KA. Structural determinants of A3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J Med Chem 2002;45:4471-4484.
74. Gao ZG, Chen A, Barak D, Kim SK, Muller CE, Jacobson KA. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem 2002;277:19056-19063.
75. Duong HT, Gao ZG, Jacobson KA. Nucleoside modification and concerted mutagenesis of the human A3 adenosine receptor to probe interactions between the 2-position of adenosine analogs and Gln167 in the second extracellular loop. Nucleosides Nucleotides Nucleic Acids 2005;24:1507-1517.
76. Jacobson KA, Gao ZG, Chen A, Barak D, Kim SA, Lee K, Link A, Rompaey PV, van Calenbergh S, Liang BT. Neoceptor concept based on molecular complementarity in GPCRs: A mutant adenosine A3 receptor with selectively enhanced affinity for amine-modified nucleosides. J Med Chem 2001;44:4125-4136.
77. IJzerman AP, Van Galen PJ, Jacobson KA. Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptor. Drug Des Discov 1992;9:49-67.
78. IJzerman AP, van der Wenden EM, van Galen PJ, Jacobson KA. Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor. Eur J Pharmacol 1994;268:95-104.
79. van Galen PJ, van Bergen AH, Gallo-Rodriguez C, Melman N, Olah ME, IJzerman AP, Stiles GL, Jacobson KA. A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol 1994;45:1101-1111.
80. Schertler GF, Villa C, Henderson R. Projection structure of rhodopsin. Nature 1993;362:770-772.
81. Unger VM, Schertler GF. Low resolution structure of bovine rhodopsin determined by electron cryomicroscopy. Biophys J 1995;68:1776-1786.
82. Unger VM, Hargrave PA, Baldwin JM, Schertler GF. Arrangement of rhodopsin transmembrane alpha-helices. Nature 1997;389:203-206.
83. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157:105-132.
84. Da Settimo F, Primofiore G, Da Settimo A, La Motta C, Taliani S, Simorini F, Novellino E, Greco G, Lavecchia A, Boldrini E. [1,2,4]Triazino[4,3-a] benzimidazole acetic acid derivatives: A new class of selective aldose reductase inhibitors. J Med Chem 2001;44:4359-4369.
85. Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA. Human P2Y1 receptor: Molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 1998;41:1456-1466.
86. Moro S, Li AH, Jacobson KA. Molecular modeling studies of human A3 adenosine antagonists: Structural homology and receptor docking. J Chem Inf Comput Sci 1998;38:1239-1248.
87. Kim YC, de Zwart M, Chang L, Moro S, von Frijtag Drabbe Kunzel JK, Melman N, IJzerman AP, Jacobson KA. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. J Med Chem 1998;41:2835-2845.
88. Li AH, Moro S, Forsyth N, Melman N, Ji XD, Jacobson KA. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem 1999;42:706-721.
89. Jiang J, Li AH, Jang SY, Chang L, Melman N, Moro S, Ji X, Lobkovsky EB, Clardy JC, Jacobson KA. Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl-1,4-dihydropyridines as selective A3 adenosine receptor antagonists. J Med Chem 1999;42:3055-3065.
90. Vedani A, Zbinden P, Snyder JP, Greenidge PA. Pseudoreceptor modeling: The construction of three-dimensional receptor surrogates. J Am Chem Soc 1995;117:4987-4994.
91. Mager PP, Reinhardt R, Richter M, Walther H, Rockel B. Molecular simulation of 8-styrylxanthines. Drug Des Discov 1995;13:89-107.
92. Mager PP, Richter M, Reinhardt R. Eur J Med Chem 1995;30:15-25.
93. Bondavalli F, Botta M, Bruno O, Ciacci A, Corelli F, Fossa P, Lucacchini A, Manetti F, Martini C, Menozzi G, Mosti L, Ranise A, Schenone S, Tafi A, Trincavelli ML. Synthesis, molecular modeling studies, and pharmacological activity of selective A1 receptor antagonists. J Med Chem 2002;45:4875-4887.
94. Ivanov AA, Baskin II, Palyulin VA, Piccagli L, Baraldi PG, Zefirov NS. Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists. J Med Chem 2005;48:6813-6820.
95. Tafi A, Bernardini C, Botta M, Corelli F, Andreini M, Martinelli A, Ortore G, Baraldi PG, Fruttarolo F, Borea PA, Tuccinardi T. Pharmacophore based receptor modeling: The case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem 2006;49:4085-4097.
96. Cruciani G, Goodford P. Copyright Molecular Discovery Ltd. 2001-2003GREATER graphical interface for GRID version, 1.1.7 GRIB, UPF/IMIM, Barcelona, Spain.
97. Catalyst 4.6, Accelrys, Inc.: 9685 Scranton Road, San Diego, CA 92121, USA.
98. Connolly M, Gschwend DA, Good AC, Oshiro C, Kuntz ID. DOCK 3.5, San Francisco, CA. Department of Pharmaceutical Chemistry, University of California, 1995.
99. Ivanov AA, Baskin II, Palyulin VA, Zefirov NS. Molecular modeling the human A1 adenosine receptor and study of the mechanisms of its selective ligand binding. Dokl Biochem Biophys 2002;386:271-274.
100. Sybyl 6.7.2. Tripos, Inc. 1699 South Hanley Road, St. Louis, MO 63144.
101. Giordanetto F, Fossa P, Menozzi G, Schenone S, Bondavalli F, Ranise A, Mosti L. Exploring the molecular basis of selectivity in A1 adenosine receptors agonists: A case study. J Comput Aided Mol Des 2003;17:39-51.
102. McMartin C, Bohacek R. QXP: Powerful, rapid computer algorithms for structure-based drug design. J Comput Aided Mol Des 1997;11:333-344.
103. Ferrarini PL, Betti L, Cavallini T, Giannaccini G, Lucacchini A, Manera C, Martinelli A, Ortore G, Saccomanni G, Tuccinardi T. Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem 2004;47:3019-3031.
104. Kehraus S, Gorzalka S, Hallmen C, Iqbal J, Muller CE, Wright AD, Wiese M, Konig GM. Novel amino acid derived natural products from the ascidian Atriolum robustum: Identification and pharmacological characterization of a unique adenosine derivative. J Med Chem 2004;47:2243-2255.
105. GOLD (Genetic Optimisation for Ligand Docking); Cambridge Crystallographic Data Centre: Cambridge, U.K., 2003.
106. Gutierrez-de-Teran H, Centeno NB, Pastor M, Sanz F. Novel approaches for modeling of the A1 adenosine receptor and its agonist binding site. Proteins 2004;54:705-715.
107. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J Comp Chem 1998;19:1639-1662.
108. Biagi G, Bianucci AM, Coi A, Costa B, Fabbrini L, Giorgi I, Livi O, Micco I, Pacchini F, Santini E, Leonardi M, Nofal FA, Salerni OL, Scartoni V. 2,9-disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: Synthesis, biochemical and molecular modelling studies. Bioorg Med Chem 2005;13:4679-4693.
109. Cappellacci L, Franchetti P, Pasqualini M, Petrelli R, Vita P, Lavecchia A, Novellino E, Costa B, Martini C, Klotz KN, Grifantini M. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. J Med Chem 2005;48:1550-1562.
110. Tuccinardi T, Ortore G, Manera C, Saccomanni G, Martinelli A. Adenosine receptor modelling. A1/A2a selectivity. Eur J Med Chem 2006;41:321-329.
111. Ivanov AA, Baskin II, Palyulin VA, Zefirov NS. Molecular modeling of the human A2A adenosine receptor. Dokl Biochem Biophys 2003;389:404-407.
112. Pastorin G, Da Ros T, Spalluto G, Deflorian F, Moro S, Cacciari B, Baraldi PG, Gessi S, Varani K, Borea PA. Pyrazolo[4,3-e]-1,2,4- triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A3 and A2B adenosine receptor subtypes: A molecular modeling investigation. J Med Chem 2003;46:4287-4296.
113. Molecular Operating Environment (MOE 2002.03): Chemical Computing Group, Inc., 1255 University Street, Suite 1600, Montreal, Quebec H3B 3X3, Canada.
114. Baraldi PG, Cacciari B, Moro S, Spalluto G, Pastorin G, Da Ros T, Klotz KN, Varani K, Gessi S, Borea PA. Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidine derivatives as human A3 adenosine receptor antagonists. J Med Chem 2002;45:770-780.
115. Costanzi S, Lambertucci C, Vittori S, Volpini R, Cristalli G. 2- and 8-Alkynyladenosines: Conformational studies and docking to human adenosine A3 receptor can explain their different biological behavior. J Mol Graph Model 2003;21:253-262.
116. Colotta V, Catarzi D, Varano F, Calabri FR, Lenzi O, Filacchioni G, Martini C, Trincavelli L, Deflorian F, Moro S. 1,2,4-Triazolo[4,3-a] quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: Synthesis, pharmacological, and ligand-receptor modeling studies. J Med Chem 2004;47:3580-3590.
117. Catarzi D, Colotta V, Varano F, Calabri FR, Lenzi O, Filacchioni G, Trincavelli L, Martini C, Tralli A, Montopoli C, Moro S. 2-Aryl-8-chloro-1,2,4- triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists. Bioorg Med Chem 2005;13:705-715.
118. Moro S, Braiuca P, Deflorian F, Ferrari C, Pastorin G, Cacciari B, Baraldi PG, Varani K, Borea PA, Spalluto G. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: Pyrazolo[4,3-e]1,2,4- triazolo[1,5-c]pyrimidine derivatives as a key study. J Med Chem 2005;48:152-162.
119. Catarzi D, Colotta V, Varano F, Lenzi O, Filacchioni G, Trincavelli L, Martini C, Montolpoli C, Moro S. 1,2,4-Triazolo-[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: Synthesis, biological evaluation and molecular modeling studies of 2-(hetero)aryl-and 2-carboxy-substituted derivatives. J Med Chem 2005;48:7932-7945.
120. Kim SK, Gao ZG, Jeong LS, Jacobson KA. Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. J Mol Graph Mod 2006;25:562-577.
121. Lenzi O, Colotta V, Catarzi D, Varano F, Filacchioni G, Martini C, Trincavelli L, Ciampi O, Varani K, Marighetti F, Morizzo E, Moro S. 4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem 2006;49:3916-3925.
122. Pastorin G, De Ros T, Bolcato C, Montopoli C, Moro S, Cacciari B, Baraldi PG, Varani K, Borea PA, Spalluto G. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5- c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations. J Med Chem 2006;49:1720-1729.
123. Oliveira L, Hulsen T, Lutje Hulsik D, Paiva AC, Vriend G. Heavier-than-air flying machines are impossible. FEBS Lett 2004;564:269-273.
124. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci 2000;9:1753-1773.
125. Chinea G, Padron G, Hooft RW, Sander C, Vriend G. The use of position-specific rotamers in model building by homology. Proteins 1995;23:415-421.
126. Flohil JA, Vriend G, Berendsen HJ. Completion and refinement of 3D homology models with restricted molecular dynamics: Application to targets 47, 58, and 111 in the CASP modeling competition and posterior analysis. Proteins 2002;48:593-604.
127. Ohno M, Gao ZG, Van Rompaey P, Tchilibon S, Kim SK, Harris BA, Gross AS, Duong HT, Van Calenbergh S, Jacobson KA. Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position. Bioorg Med Chem 2004;12:2995-3007.
128. Tchilibon S, Kim SK, Gao ZG, Harris BA, Blaustein JB, Gross AS, Duong HT, Melman N, Jacobson KA. Exploring distal regions of the A3 adenosine receptor binding site: Sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg Med Chem 2004;12:2021-2034.
129. Depriest SA, Mayer D, Naylor CB, Marshall GR. 3D-QSAR of angiotensin-converting enzyme and fhermolysin inhibitors: A comparison of CoMFA models based on deduced and experimentally determined active-site geometries. J Am Chem Soc 1993;115:5372-5384.
130. Waller CL, Oprea TI, Giolitti A, Marshall GR. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. J Med Chem 1993;36:4152-4160.
131. Lyne PD. Structure-based virtual screening: An overview. Drug Discov Today 2002;7:1047-1055.
132. Jalaie M, Erickson JA. Homology model directed alignment selection for comparative molecular field analysis: Application to photosystem II inhibitors. J Comput Aided Mol Des 2000;14:181-197.
133. Gamper AM, Winger RH, Liedl KR, Sotriffer CA, Varga JM, Kroemer RT, Rode BM. Comparative molecular field analysis of haptens docked to the multispecific antibody IgE(Lb4). J Med Chem 1996;39:3882-3888.
134. Tuccinardi T, Calderone V, Rapposelli S, Martinelli A. Proposal of a new binding orientation for non-peptide AT1 antagonists: Homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis. J Med Chem 2006;49:4305-4316.
135. de Ligt RA, Rivkees SA, Lorenzen A, Leurs R, IJzerman AP. A "locked-on," constitutively active mutant of the adenosine A1 receptor. Eur J Pharmacol 2005;510:1-8.
136. Borhan B, Souto ML, Imai H, Shichida Y, Nakanishi K. Movement of retinal along the visual transduction path. Science 2000;288:2209-2212.
137. Meng EC, Bourne HR. Receptor activation: What does the rhodopsin structure tell us? Trends Pharmacol Sci 2001;22:587-593.
138. Klein-Seetharaman J, Hwa J, Cai K, Altenbach C, Hubbell WL, Khorana HG. Single-cysteine substitution mutants at amino acid positions 55-75, the sequence connecting the cytoplasmic ends of helices I and II in rhodopsin: Reactivity of the sulfhydryl groups and their derivatives identifies a tertiary structure that changes upon light-activation. Biochemistry 1999;38:7938-7944.
139. Jensen AD, Guarnieri F, Rasmussen SG, Asmar F, Ballesteros JA, Gether U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 2001;276:9279-9290.
140. Porter JE, Hwa J, Perez DM. Activation of the alphalb-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. J Biol Chem 1996;271:28318-28323.
141. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 2002;277:40989-40996.
142. http://physiology.med.cornell.edu/GPCRactivation/gpcrindex.html.
143. Salom D, Lodowski DT, Stenkamp RE, Le Trong I, Golczak M, Jastrzebska B, Harris T, Ballesteros JA, Palczewski K. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. PNAS 2006;103:16123-16128.
144. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 1996;274:768-770.
145. Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, Bourne HR. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature 1996;383:347-350.
146. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK. Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J 1997;16:6737-6747.
147. Javitch JA, Fu D, Liapakis G, Chen J. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 1997;272:18546-18549.
148. Rasmussen SG, Jensen AD, Liapakis G, Ghanouni P, Javitch JA, Gether U. Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: Constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. Mol Pharmacol 1999;56:175-184.
149. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, Javitch JA. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001;276:29171-29177.
150. Lin SW, Sakmar TP. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 1996;35:11149-11159.
151. Singh R, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Guarnieri F. Activation of the cannabinoid CB1 receptor may involve a W6 48/F3 36 rotamer toggle switch. J Pept Res 2002;60:357-370.
152. Gao ZG, Kim SK, Ijzerman AP, Jacobson KA. Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem 2005;5:545-553.
153. Baraldi PG, Moorman AR, Tabrizi MA, Pavani MG, Romagnoli R. Allosteric modulators for the A1 adenosine receptor. Expert Opin Ther Pat 2004;14:71-79.
154. Olsson RA. Allosteric enhancers for adenosine receptors. Drug Dev Res 2003;58:493-495.